Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/08/2859061/0/en/Principal-Investigator-from-City-of-Hope-National-Medical-Center-Invited-to-Present-Clinical-Data-from-Marker-Therapeutics-APOLLO-Study-at-11th-Global-Summit-on-Hematologic-Maligna.html
https://www.globenewswire.com/news-release/2024/03/25/2852040/0/en/Marker-Therapeutics-Reports-Year-End-2023-Corporate-and-Financial-Results.html
https://www.globenewswire.com/news-release/2024/03/22/2851079/0/en/Marker-Therapeutics-to-Present-at-the-H-C-Wainwright-2nd-Annual-Cell-Therapy-Virtual-Conference.html
https://www.globenewswire.com//news-release/2024/01/22/2812937/0/en/Marker-Therapeutics-Receives-Approval-from-United-States-Adopted-Name-USAN-Council-and-International-Nonproprietary-Names-INN-Expert-Committee-for-Neldaleucel-as-Nonproprietary-Nam.html
https://www.globenewswire.com//news-release/2024/01/08/2805437/0/en/Marker-Therapeutics-Announces-Clinical-Program-Updates-and-Pipeline-Prioritization.html
https://www.globenewswire.com//news-release/2023/12/21/2800165/0/en/Marker-Therapeutics-Announces-Participation-in-Biotech-Showcase-and-the-19th-Annual-Non-Dilutive-Funding-Summit-During-J-P-Morgan-Week-2024.html
https://www.globenewswire.com//news-release/2023/12/11/2793733/0/en/Marker-Therapeutics-Announces-Sustained-Complete-Response-in-First-Lymphoma-Patient-Treated-with-MT-601-following-CAR-T-Relapse.html
https://www.globenewswire.com//news-release/2023/11/09/2777937/0/en/Marker-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html
https://www.globenewswire.com//news-release/2023/09/11/2740646/0/en/Marker-Therapeutics-Announces-Complete-Response-in-First-Lymphoma-Patient-Treated-with-MT-601-after-CAR-T-Relapse.html
https://www.globenewswire.com//news-release/2023/08/30/2734294/0/en/Marker-Therapeutics-to-Present-at-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html